Drug company merger should benefit research

被引：0

|

作者：

Labreque, G

机构：

来源：

BRITISH MEDICAL JOURNAL | 1998年 / 316卷 / 7130期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：494 / 494

页数：1

相关论文

共 50 条

[41] Should benefit-risk assessment have its own drug "label"?
Braithwaite, R. Scott
DRUG HEALTHCARE AND PATIENT SAFETY, 2011, 3 : 37 - 41
[42] Old news - Why Big Pharm should love a drug benefit.
Easterbrook, G
NEW REPUBLIC, 2000, 223 (18) : 22 - +
[43] Benefit allocation after the merger of electricity markets
Ruiz, PA
37TH NORTH AMERICAN POWER SYMPOSIUM, PROCEEDINGS, 2005, : 503 - 508
[44] Agema merger with FSI to benefit industrial sector
不详
INSIGHT, 1998, 40 (03) : 153 - 153
[45] IN A MERGER, CONSIDER ALL EMPLOYEE BENEFIT FUNDING
EMERING, EJ
HARVARD BUSINESS REVIEW, 1982, 60 (01) : 46 - &
[46] New drug research company will use human tissue for testing
不详
BIOSENSORS & BIOELECTRONICS, 1997, 12 (01): : R3 - R4
[47] RESEARCH RESOURCES MERGER
HOLDEN, C
SCIENCE, 1988, 242 (4879) : 665 - 665
[48] MERGER ACTIVITY AND SALES OF SUBSIDIARIES BETWEEN COMPANY GROUPS
LYE, S
SILBERTSON, A
OXFORD BULLETIN OF ECONOMICS AND STATISTICS, 1981, 43 (03) : 257 - 272
[49] Merger creates second largest metallurgical coal company
不详
MINING ENGINEERING, 2003, 55 (02) : 13 - 13
[50] VALUATION OF COMPANY MERGER FROM THE SHAREHOLDERS' POINT OF VIEW
Toll, Christian
Hering, Thomas
AMFITEATRU ECONOMIC, 2017, 19 (46) : 836 - 852

← 1 2 3 4 5 →